Ghent University Academic Bibliography

Advanced

Once-yearly zoledronic acid in older men compared with women with recent hip fracture

Steven Boonen, Eric Orwoll, Jay Magaziner, Cathleen S Colón-Emeric, Jonathan D Adachi, Christina Bucci-Rechtweg, Patrick Haentjens, Jean Kaufman UGent, Rene Rizzoli, Dirk Vanderschueren, et al. (2011) JOURNAL OF THE AMERICAN GERIATRICS SOCIETY. 59(11). p.2084-2090
abstract
OBJECTIVES: To assess the efficacy of once-yearly zoledronic acid (ZOL) 5 mg in increasing bone mineral density (BMD) in men with a recent hip fracture participating in the Health Outcomes and Reduced Incidence with Zoledronic Acid Once-Yearly Recurrent Fracture Trial and to compare the efficacy with that in women from the same study. DESIGN: Randomized, placebo-controlled, double-blind trial. SETTING: International multicenter. PARTICIPANTS: Five hundred and eight men and 1,619 women within 90 days of surgical repair of low-trauma hip fracture in the same study (for comparison). INTERVENTION: Once-yearly intravenous (IV) ZOL 5 mg (n = 248) or placebo (n = 260), loading dose of vitamin D, daily calcium, and vitamin D supplements. MEASUREMENT: Changes in BMD. RESULTS: Percentage change from baseline in total hip BMD at Months 12 and 24 was significantly higher with ZOL than with placebo (between-group difference, 2.0%, P = .003, and 3.8%, P = .002, respectively). Percentage change from baseline in femoral neck BMD at Month 24 was significantly higher with ZOL than with placebo (3.8%, P = .003). The BMD benefit was comparable with that observed in women in this study. New clinical fractures occurred in 36 (7.1%) participants (ZOL, n = 16; placebo, n = 20; P = .64). The ZOL safety profile was comparable with that of placebo, with no significant differences in cardiovascular or long-term renal function and a trend toward lower mortality in ZOL-treated men. CONCLUSION: Once-yearly IV ZOL 5 mg increases bone mass at the hip and femoral neck in men within 90 days of repair of a low-trauma hip fracture. Increases were of a similar magnitude to those observed in women in the same study.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
men, once-yearly, hip fracture, bone mineral density, osteoporosis, BONE-MINERAL DENSITY, EXCESS MORTALITY, DOUBLE-BLIND, OSTEOPOROTIC FRACTURE, MULTICENTER, SURVIVAL, RISK, METAANALYSIS, RISEDRONATE, ALENDRONATE
journal title
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
J. Am. Geriatr. Soc.
volume
59
issue
11
pages
2084 - 2090
Web of Science type
Article
Web of Science id
000297411000012
JCR category
GERONTOLOGY
JCR impact factor
3.737 (2011)
JCR rank
2/30 (2011)
JCR quartile
1 (2011)
ISSN
0002-8614
DOI
10.1111/j.1532-5415.2011.03666.x
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
2139182
handle
http://hdl.handle.net/1854/LU-2139182
date created
2012-06-11 14:43:02
date last changed
2016-12-19 15:42:08
@article{2139182,
  abstract     = {OBJECTIVES: To assess the efficacy of once-yearly zoledronic acid (ZOL) 5 mg in increasing bone mineral density (BMD) in men with a recent hip fracture participating in the Health Outcomes and Reduced Incidence with Zoledronic Acid Once-Yearly Recurrent Fracture Trial and to compare the efficacy with that in women from the same study. 
DESIGN: Randomized, placebo-controlled, double-blind trial. 
SETTING: International multicenter. 
PARTICIPANTS: Five hundred and eight men and 1,619 women within 90 days of surgical repair of low-trauma hip fracture in the same study (for comparison). 
INTERVENTION: Once-yearly intravenous (IV) ZOL 5 mg (n = 248) or placebo (n = 260), loading dose of vitamin D, daily calcium, and vitamin D supplements. 
MEASUREMENT: Changes in BMD. 
RESULTS: Percentage change from baseline in total hip BMD at Months 12 and 24 was significantly higher with ZOL than with placebo (between-group difference, 2.0\%, P = .003, and 3.8\%, P = .002, respectively). Percentage change from baseline in femoral neck BMD at Month 24 was significantly higher with ZOL than with placebo (3.8\%, P = .003). The BMD benefit was comparable with that observed in women in this study. New clinical fractures occurred in 36 (7.1\%) participants (ZOL, n = 16; placebo, n = 20; P = .64). The ZOL safety profile was comparable with that of placebo, with no significant differences in cardiovascular or long-term renal function and a trend toward lower mortality in ZOL-treated men. 
CONCLUSION: Once-yearly IV ZOL 5 mg increases bone mass at the hip and femoral neck in men within 90 days of repair of a low-trauma hip fracture. Increases were of a similar magnitude to those observed in women in the same study.},
  author       = {Boonen, Steven and Orwoll, Eric and Magaziner, Jay and Col{\'o}n-Emeric, Cathleen S and Adachi, Jonathan D and Bucci-Rechtweg, Christina and Haentjens, Patrick and Kaufman, Jean and Rizzoli, Rene and Vanderschueren, Dirk and Claessens, Frank and Sermon, An and Witvrouw, Richard and Milisen, Koen and Su, Guoqin and Lyles, Kenneth W},
  issn         = {0002-8614},
  journal      = {JOURNAL OF THE AMERICAN GERIATRICS SOCIETY},
  keyword      = {men,once-yearly,hip fracture,bone mineral density,osteoporosis,BONE-MINERAL DENSITY,EXCESS MORTALITY,DOUBLE-BLIND,OSTEOPOROTIC FRACTURE,MULTICENTER,SURVIVAL,RISK,METAANALYSIS,RISEDRONATE,ALENDRONATE},
  language     = {eng},
  number       = {11},
  pages        = {2084--2090},
  title        = {Once-yearly zoledronic acid in older men compared with women with recent hip fracture},
  url          = {http://dx.doi.org/10.1111/j.1532-5415.2011.03666.x},
  volume       = {59},
  year         = {2011},
}

Chicago
Boonen, Steven, Eric Orwoll, Jay Magaziner, Cathleen S Colón-Emeric, Jonathan D Adachi, Christina Bucci-Rechtweg, Patrick Haentjens, et al. 2011. “Once-yearly Zoledronic Acid in Older Men Compared with Women with Recent Hip Fracture.” Journal of the American Geriatrics Society 59 (11): 2084–2090.
APA
Boonen, Steven, Orwoll, E., Magaziner, J., Colón-Emeric, C. S., Adachi, J. D., Bucci-Rechtweg, C., Haentjens, P., et al. (2011). Once-yearly zoledronic acid in older men compared with women with recent hip fracture. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 59(11), 2084–2090.
Vancouver
1.
Boonen S, Orwoll E, Magaziner J, Colón-Emeric CS, Adachi JD, Bucci-Rechtweg C, et al. Once-yearly zoledronic acid in older men compared with women with recent hip fracture. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY. 2011;59(11):2084–90.
MLA
Boonen, Steven, Eric Orwoll, Jay Magaziner, et al. “Once-yearly Zoledronic Acid in Older Men Compared with Women with Recent Hip Fracture.” JOURNAL OF THE AMERICAN GERIATRICS SOCIETY 59.11 (2011): 2084–2090. Print.